KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Novartis Ag (NVS) Liabilities from Discontinued Operations (2018 - 2023)

Novartis Ag's Liabilities from Discontinued Operations history spans 4 years, with the latest figure at 34000000.0 for Q2 2023.

On a quarterly basis, Liabilities from Discontinued Operations changed N/A to 34000000.0 in Q2 2023 year-over-year; TTM through Jun 2023 was 34000000.0, a N/A change, with the full-year FY2019 number at 31000000.0, down 39.22% from a year prior.
Liabilities from Discontinued Operations hit 34000000.0 in Q2 2023 for Novartis Ag, up from 31000000.0 in the prior quarter.
Over the last five years, Liabilities from Discontinued Operations for NVS hit a ceiling of 50000000.0 in Q2 2019 and a floor of 24000000.0 in Q3 2019.